Axsome Therapeutics (AXSM) Misses Q2 EPS by 30c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts AXSM Hot Sheet
Join SI Premium – FREE
Axsome Therapeutics (NASDAQ: AXSM) reported Q2 EPS of ($1.54), $0.30 worse than the analyst estimate of ($1.24). Revenue for the quarter came in at $46.01 million versus the consensus estimate of $40.89 million.
For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Goldman Sachs sees US stocks dip on tech earnings and macro shifts
- Mizuho on Axsome Therapeutics (AXSM): 'recommend buying ahead of AXSM's 3Q print'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
